Fig. 3: Antigen-specific anti-tumor effects of CAR-Ms induced by CARmRNA@aCD206 sEVs in vitro. | Nature Communications

Fig. 3: Antigen-specific anti-tumor effects of CAR-Ms induced by CARmRNA@aCD206 sEVs in vitro.

From: Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles

Fig. 3

a Phagocytosis of M2 BMDMs pre-treated with the indicated sEVs to CFSE-labeled B16 (MSLN−) cells or B16-MSLN (MSLN+) cells, as determined by flow cytometry (n = 5 independent experiments). b Representative confocal microscopy images showing the phagocytosis of B16-MSLN cells by M2 BMDMs pre-treated with the indicated sEVs. Macrophages were labeled with DiO (green) and B16-MSLN cells were labeled with DiI (red). Experiment was repeated three times independently with similar results. Scale bar: 20 μm. Cytotoxicity of M2 BMDMs pre-treated with the indicated sEVs against c B16 cells and d B16-MSLN cells at effector (pre-treated M2 BMDMs) to target (B16 or B16-MSLN cells) ratios of 10:1, 5:1, 2:1, 1:1 or 1:2 (n = 3 independent experiments). Cytokine concentrations of e IFN-γ, f TNF-α, and g IL-10 released by M2 BMDMs pre-treated with indicated sEVs after co-incubation with B16-MSLN cells (n = 6 independent experiments). G1: PBS, G2: MockmRNA@aCD206 sEV, G3: CARmRNA@sEV, G4: CARmRNA@aCD206 sEV. For (a–g), the dosage of sEVs used was 4 × 106 mRNA copies/mL. Data are presented as mean ± SD. Data were analyzed using one-way ANOVA with Tukey’s test in (a) and (e–g). **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, ns: not significant. Source data are provided as a Source Data file.

Back to article page